Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing.

Trkulja, Vladimir

Trkulja, Vladimir.

Trkulja V; Department of Pharmacology, Zagreb University School of Medicine, Salata 11, 10000, Zagreb, Croatia. vladimir.trkulja@mef.hr.

Eur J Clin Pharmacol ; 77(6): 935-937, 2021 Jun.

Article in English | MEDLINE | ID: covidwho-1009115

Subject(s)

Adenosine Monophosphate/analogs & derivatives; Alanine/analogs & derivatives; COVID-19 Drug Treatment; COVID-19; Pneumonia, Viral; Respiratory Insufficiency; Time-to-Treatment; Adenosine Monophosphate/administration & dosage; Airway Management/methods; Alanine/administration & dosage; Antiviral Agents/administration & dosage; COVID-19/diagnosis; COVID-19/mortality; COVID-19/physiopathology; Disease Progression; Humans; Hypoxia/etiology; Hypoxia/therapy; Mortality; Patient Selection; Pneumonia, Viral/etiology; Pneumonia, Viral/physiopathology; Pneumonia, Viral/therapy; Randomized Controlled Trials as Topic; Respiratory Insufficiency/blood; Respiratory Insufficiency/etiology; Respiratory Insufficiency/therapy; SARS-CoV-2; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Respiratory Insufficiency / Adenosine Monophosphate / Alanine / Time-to-Treatment / COVID-19 / COVID-19 Drug Treatment Type of study: Diagnostic study / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Eur J Clin Pharmacol Year: 2021 Document Type: Article Affiliation country: S00228-020-03085-7

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google